Recruiting

Genetic Testing

Sponsor:

Columbia University

Code:

NCT01102569

Conditions

Pancreatic Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may have a significant impact; allowing for early screening, treatment, and resection of pre-malignant tissue or malignant lesions.

Conditions

Pancreatic Cancer

Study ID

NCT01102569

Start date

Jan, 2008

Status verified date

Apr, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients diagnosed with pancreatic cancer.
  • Patients are of Ashkenazi Jewish descent.
  • Patients have been Columbia Pancreatic Cancer Prevention Program Registry and Tissue Bank for High-Risk Individuals (IRB-AAAA6154).

Exclusion Criteria:

  • Inability to provide informed consent.
  • Under the age of 18 years old.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Pancreatic cancer and Ashkenazi decent

Patients with pancreatic cancer will be asked to join the study if they identify themselves as being of Ashkenazi descent, as well as patients at a high-risk of pancreas cancer based on family history, and will be followed from the time of diagnosis.

Primary outcome measure

  • Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Fay Kastrinos, MD

212-305-1021fk18@columbia.edu

Vilma Rosario

212-305-6033vr2222@columbia.edu

Locations

Columbia University Medical Center

Recruiting

New York, New York, United States, 10032

Contacts

Fay Kastrinos, MD

212-305-1021fk18@columbia.edu

Vilma Rosario

212-305-6033vr2222@columbia.edu

Principal Investigator:

Fay Kastrinos, MD

More Information

Sponsor

Columbia University

Last update posted

May 6, 2026

Last verified

Apr, 2026

Keywords

  • Hereditary pancreatic cancer
  • Breast and Ovarian Cancer Syndrome
  • BRCA1/2
  • Ashkenazi Jewish patients

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Columbia University on 2026-05-06.